Eliem Therapeutics, Inc. (NASDAQ:ELYM - Get Free Report) saw a large increase in short interest in April. As of April 15th, there was short interest totalling 601,100 shares, an increase of 4,453.8% from the March 31st total of 13,200 shares. Approximately 3.3% of the company's stock are short sold. Based on an average daily volume of 665,800 shares, the short-interest ratio is currently 0.9 days.
Eliem Therapeutics Stock Down 7.4 %
Shares of ELYM traded down $0.27 during trading on Thursday, reaching $3.39. The company's stock had a trading volume of 388,878 shares, compared to its average volume of 567,939. The company has a fifty day moving average of $3.04 and a two-hundred day moving average of $2.79. Eliem Therapeutics has a twelve month low of $2.34 and a twelve month high of $5.19. The company has a market cap of $93.97 million, a price-to-earnings ratio of -2.31 and a beta of 0.51.
Hedge Funds Weigh In On Eliem Therapeutics
An institutional investor recently bought a new position in Eliem Therapeutics stock. Cerity Partners LLC purchased a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,821 shares of the company's stock, valued at approximately $37,000. Cerity Partners LLC owned approximately 0.05% of Eliem Therapeutics at the end of the most recent quarter. 69.76% of the stock is currently owned by hedge funds and other institutional investors.
Eliem Therapeutics Company Profile
(
Get Free Report)
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Recommended Stories
Before you consider Eliem Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eliem Therapeutics wasn't on the list.
While Eliem Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
